New targets for the treatment of follicular lymphoma

Authors

Nishant Tageja, Wayne State University School of MedicineFollow
Subhash Padheye, D.Y. Patil University, IndiaFollow
Prasad Dandawate, D.Y. Patil University, IndiaFollow
Ayad Al-Katib, Wayne State University School of MedicineFollow
Ramzi M. Mohammad, Wayne State University School of MedicineFollow

Document Type

Article

Abstract

Abstract

The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have improved the outlook for many individuals with these disorders; however, with these advances come new questions. Given the long-term survival of patients with FL, drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is imperative to exploit the biology of FL while inherently preventing relapse and prolonging survival. This review summarizes the growing body of knowledge regarding novel therapeutic targets, enabling the concept of individualized targeted therapy for the treatment of FL.

Disciplines

Oncology

Recommended Citation

Tageja et al. Journal of Hematology & Oncology 2009, 2:50
doi:10.1186/1756-8722-2-50